Long noncoding RNA in prostate, bladder, and kidney cancer

Elena S. Martens-Uzunova, René Böttcher, Carlo M. Croce, Guido Jenster, Tapio Visakorpi, George A. Calin

Research output: Contribution to journalArticleScientificpeer-review

432 Citations (Scopus)


Context Genomic regions without protein-coding potential give rise to millions of protein-noncoding RNA transcripts (noncoding RNA) that participate in virtually all cellular processes. Research over the last 10 yr has accumulated evidence that long noncoding RNAs (lncRNAs) are often altered in human urologic cancers. Objective To review current progress in the biology and implication of lncRNAs associated with prostate, bladder, and kidney cancer. Evidence acquisition The PubMed database was searched for articles in the English language with combinations of the Medical Subject Headings terms long non coding RNA, long noncoding RNA, long untranslated RNA, cancer, neoplasms, prostate, bladder, and kidney. Evidence synthesis We summarise existing knowledge on the systematics, biology, and function of lncRNAs, particularly these involved in prostate, kidney, and bladder cancer. We also discuss the possible utilisation of lncRNAs as novel biomarkers and potential therapeutic targets in urologic malignancies and portray the major challenges and future perspectives of ongoing lncRNA research. Conclusions LncRNAs are important regulators of gene expression interacting with the major pathways of cell growth, proliferation, differentiation, and survival. Alterations in the function of lncRNAs promote tumour formation, progression, and metastasis of prostate, bladder, and kidney cancer. LncRNAs can be used as noninvasive tumour markers in urologic malignancies. Increased knowledge of the molecular mechanisms by which lncRNAs perform their function in the normal and malignant cell will lead to a better understanding of tumour biology and could provide novel therapeutic targets for the treatment of urologic cancers. Patient summary In this paper we reviewed current knowledge of long noncoding RNAs (lncRNAs) for the detection and treatment of urologic cancers. We conclude that lncRNAs can be used as novel biomarkers in prostate, kidney, or bladder cancer. LncRNAs hold promise as future therapeutic targets, but more research is needed to gain a better understanding of their biologic function.

Original languageEnglish
Pages (from-to)1140-1151
Number of pages12
JournalEuropean Urology
Issue number6
Publication statusPublished - 2014
Publication typeA1 Journal article-refereed


  • Beckwith-Wiedemann syndrome
  • Bladder cancer
  • Kidney cancer
  • Long noncoding RNA
  • Prostate cancer
  • Renal cell carcinoma
  • Urothelial carcinoma
  • Wilms tumour
  • bladder cancer
  • kidney cancer
  • lncRNA
  • long non-coding RNA
  • prostate cancer

Publication forum classification

  • Publication forum level 2


Dive into the research topics of 'Long noncoding RNA in prostate, bladder, and kidney cancer'. Together they form a unique fingerprint.

Cite this